• PDF: Delivered by email usually within 4 to 8 UK business hours.
  • PRINT/CD-ROM: Despatched within 1 to 2 working days.

Global Image Dermatology Drug Market, 2005-2012, The
High-Growth Opportunities in Aesthetic Medicine

Global Image Dermatology Drug Market, 2005-2012, The High-Growth Opportunities in Aesthetic Medicine

Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form. Drugs such as botulinum toxins, retinoids, acid peels, 5-alpha reductase and lipase inhibitors associated with cutaneous ageing, photodamage, pigmentation defects, alopecia, and the lipodermal disorders of obesity and gynoid lipodystrophy are critically discussed to provide a detailed analysis of the high-growth market sector estimated at US$1.8 billion in 2005 and forecast to increase by 114% to US$3.9 billion by 2012. The report includes insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to gain insight into top-performing products and therapy areas.

Report Highlights and Key Findings

  • Dermatological drugs indicated for image dermatology account for a market valued at US$1.8 billion, which is predicted to increase 114% CAGR to 2012
  • Critical analysis of alopecia, cutaneous ageing, photodamage, pigmentation deficits, obesity, cellulite and other lipodermal conditions
  • Comprehensive review of epidemiological, aetiological, and therapeutic data for 5 key therapy areas
  • Analysis of over 20 marketed products and inclusion of 45 R&D candidates identified in preclinical to clinical stages of development
  • Sales estimates (US$) to 2012 for critical therapy areas
  • Strategic insights for life-cycle optimization and product development
  • Evaluation of leading products and major competitors
  • Emerging markets identified and sector analysis
  • Trend analysis of industry events and activities over past 2 years
  • Detailed R&D themes and clusters by therapy area
  • Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
  • High revenue-yielding prospects identified with projected sales estimations
  • R&D pipeline positioning for all therapy areas
  • Market insights for product development and drug promotion

What Can I Learn from This Report?

  • What the main therapy areas are within the image dermatology field
  • What the current treatment options are for alopecia, cutaneous ageing, photodamage, hyperand hypopigmentation disorders, and obesity
  • Who the market leaders are in the image dermatology field
  • Which premarket drugs are identified as potential blockbusters
  • What factors are involved in driving the aesthetic dermatology market
  • What the sales predictions are for botulinum toxins, retinoids, anorectics, lipase inhibitors, 5-alpha reductase inhibitors, antiandrogenics, hydroquinones, and tretinoin to 2012
  • Which therapy areas are forecast for high-value growth over the next decade
  • Which companies are developing novel drugs for aesthetic indications
  • What are the unmet needs in the antiageing and image dermatology field
  • Which therapy areas are niche market opportunities
  • What the future outlook holds for marketed dermatologicals associated with ageing or lifestyle dissatisfaction
  • What the research and development trends are in image dermatology
  • Which molecules and compounds are being evaluated with potential indications for antiageing, aesthetics or lifestyle
  • Which are the top prospects for image dermatology over the next decade and to 2020

Companies Mentioned in Report

  • Abbott Laboratories Serono
  • Alizyme Shionogi
  • Allergan Solvay Pharmaceuticals
  • Amgen Stiefel Laboratories
  • Amylin Pharmaceuticals Targacept
  • Arena Pharmaceuticals Valeant Pharmaceuticals
  • Astellas Pharma Vernalis
  • Barrier Therapeutics Wyeth
  • Bertek Pharmaceuticals
  • Bioaccelerate
  • Biotecon Therapeutics
  • Biovitrium
  • Bristol-Myers Squibb
  • CHIRON
  • CURIS
  • Dainippon Sumitomo Pharmaceuticals
  • EISAI
  • ELAN
  • Enhance Biotech
  • EPITAN
  • FASGEN
  • Galderma
  • Genaera
  • Glades Pharmaceuticals
  • Glaxosmithkline
  • Genaderm
  • INAMED
  • Intercytex
  • IPSEN
  • Isolagen
  • Karo Bio
  • LIGAND
  • MENTOR
  • MERCK
  • Merz Pharma
  • Metabolic Pharmaceuticals
  • Millennium
  • Nastech
  • Neurogen
  • Obagi Medical Products
  • ORTHO-MCNEIL PHARMACEUTICALS
  • PFIZER
  • Pherin Pharmaceuticals
  • Predix Pharma
  • Phytopharm
  • ROCHE
  • Sanofi-Aventis
  • Sapphiretherapeutics
  • Executive Summary
  • Objectives of the Report Briefing
  • Research Methodology
  • Chapter 1 Introduction to Antiageing and Image Dermatology
    • Ageing and life Enhancement
    • What are Antiageing and Life Enhancement Pharmacotherapies?
    • Ageing, Lifestyle Conditions, and Dermatology
    • Alopecia
    • Prevalence of Alopecia
    • Alopecia as a Lifestyle Problem
    • The Normal Hair Growth Cycle
    • Types of Alopecia
    • Dermal Ageing
    • Photodamage and Solar Radiation
    • Pollution and Dermal Damage
    • Dermal Pigmentation
    • Hyerpigmentation and Hypopigmentation Disorders
    • Biological Basis to Pigmentation: Melanogenesis and Photoprotection
    • Cellular Mechanisms of Melanogenesis and Photoprotection
    • Hyperpigmentation Disorders
    • Hypopigmentation Disorders
    • Vitiligo
    • Albinism
    • Postinflammatory Hypopigmentation
    • Lipodermal Disorders
    • Gynoid Lipodystrophy
    • The Development of Cellulite
    • Treatments Options for Cellulite
    • Obesity
    • Obesity Prevalence
    • Types of Obesity
    • Measuring and Diagnosing Obesity
    • Aetiological Aspects of Obesity
    • Physiological Aspects of Hunger and Satiety
    • Health Risks of Obesity
    • Psychosocial Aspects of Obesity
  • Chapter 2 Image Dermatology Drug Markets
    • Alopecia
    • Alopecia Drug Market Overview
    • Market Forecasts for Alopecia Products
    • Market Analysis for the Alopecia Drug Market
    • Propecia (Finasteride) - Merck
    • Rogaine/Regaine (Minoxidil) - Pfizer
    • Product Extension Strategy Insights for Alopecia Products
    • Product Extension Strategy Insights for Finasteride
    • Product Extension Strategy Insights for Minoxidil
    • Future Considerations for Drugs to Treat Alopecia
    • Drug Development Prospects
    • BIO024 - Genaderm
    • Other Clinical Candidates
    • Cutaneous Ageing
    • Dermal Ageing Product Market Overview
    • Market Forecasts for Dermal Ageing Products
    • Market Analysis for Cutaneous Ageing/Photodamage Products
    • Market Insights and Strategies for the Botulinum Toxin Sector
    • Direct Competition to Botox
    • Botulinum Toxin Products in Asia and South America
    • Product Extension Strategy Insights for Botulinum Toxin Products
    • Market Insights and Strategies for the Topical Antiageing Product Sector
    • Product Extension Strategy Insights for Topical Antiageing Products
    • Tretinoin
    • Isotretinoin
    • Tazarotene
    • Idebenone
    • Acid Peel Products
    • Future Considerations and Market Insights for the Cutaneous Antiageing
    • Product Sector
    • Dermal Pigmentation Conditions
    • Market Forecasts for Dermal Pigmentation Products
    • Market Analysis of the Dermal Pigmentation Product Sector
    • Market Insights and Potential Product Development Strategies for Hyperpigmentation
    • Conditions
    • Hydroquinone
    • Tretinoin
    • Azelaic Acid
    • Market Insights and Potential Product Development Strategies for Hypopigmentation
    • Conditions
    • Induced Photoprotective Melanogenesis
    • Therapeutic, Prophylactic, and Cosmetic Markets for Photoprotective Melanogenesis
    • Solar Allergies/Polymorphous Light Eruption
    • Other Hypopigmentation Conditions
    • Skin Cancer Prophylaxis
    • Cosmetic-Medical Indications
    • Future Considerations and Market Outlook for the Dermal Pigmentation Therapy Area
    • Lipodermal Conditions
    • Gynoid Lipodystrophy (Cellulite)
    • Novel Pharmacotherapeutics for Cellulite
    • BIO303 - Enhance Biotech/Bioaccelerate
    • Phosphatidylcholine (Lecithin)
    • Redeveloping Old Molecules for New Cosmetic Indications
    • Obesity
    • Market Analysis for Antiobesity Drugs
    • Market Forecasts for Antiobesity Drugs
    • Antiobesity Product Extension Strategies and Insights
    • Sibutramine - (Meridia/Reductil) Abbott Laboratories
    • Market Outlook for Sibutramine
    • Orlistat
    • Class Competition - ATL-962 (Cetilistat) Alizyme
    • Product Extension Strategy Insights for Orlistat
    • Antiobesity Drugs at the Premarket Authorization Stage
    • Rimonabant
    • Safety and Efficacy Data
    • Lipodermal Disorders - Future Considerations and Market Insights
    • Gynoid Lipodystrophy
    • Obesity
    • Emerging Weight Regulation and Lipid Metabolism Market Opportunities
    • Appetite Stimulation
    • Lipodystrophies
  • Chapter 3 Drugs in Research and Development
    • Introduction
    • Alopecia
    • Research and Development Overview
    • Hedgehog Agonists - Curis
    • ICX-TRC - Intercytex
    • BIO024 - Genaderm/Bioaccelerate
    • Dermal Ageing
    • Research and Development Overview
    • Dysport/Reloxin - Ipsen/Inamed
    • Autologous Cell Therapy - Isolagen
    • 17-Beta Oestradiol (E2) - University of Michigan/Pfizer
    • Pigmentation Conditions
    • Research and Development Overview
    • EPT1647 - Epitan
    • Lipodermal Conditions
    • Gynoid Lipodystrophy
    • Research and Development Overview
    • BIO303 - Enhance Biotech/Bioaccelerate
    • Obesity
    • Research and Development Overview
  • Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
    • Introduction: Data Analysis, Therapy Forecasting, and Prospect Mining
    • Market Analysis and Therapy Forecasting
    • Dermatology: Alopecia, Dermal Ageing, Pigmentation Disorders and
    • Lipodermal Conditions
    • Therapy Area Forecasts
    • Market Share of Dermatological Therapy Areas
    • Comparative Analysis: Product Sales
    • Dermatology Therapy Areas
    • Prospect Mining
    • Dermatological Drug Prospects in the Antiageing and Life Enhancement
    • Therapy Market
    • Alopecia
    • Dermal Ageing
    • Dermal Pigmentation
    • Lipodermal Conditions
  • Chapter 5 Report Synopsis
    • Dermatology
    • Alopecia - Key Data Points
    • Dermal Ageing and Pigmentation Disorders - Key Data Points
    • Lipodermal Conditions - Key Data Points
    • Bibliography and Reference Sources
  • List of Tables
    • Table 1.1 Types of Alopecia
    • Table 1.2 Features of Intrinsic Chronological Cutaneous Ageing and Photoageing
    • Table 1.3 Factors Associated with Dermal Ageing
    • Table 1.4 Types of Solar Radiation
    • Table 1.5 Common Hyperpigmentation Disorders
    • Table 1.6 Types of Hypopigmentation Disorders
    • Table 1.7 Calculating Body Mass Index
    • Table 1.8 Aetiological Factors Associated with Obesity
    • Table 1.9 Health Risks and Comorbidities Associated with Obesity
    • Table 1.10 Psychological, Behavioural, and Socioenvironmental Factors Associated with Obesity
    • Table 2.1 Estimated Global Sales & Forecasts of Drugs for Alopecia (US$m), 2004-2012
    • Table 2.2 Estimated Global Sales & Forecasts of Dermal Antiageing Products, 2004-2012
    • Table 2.3 Topical Antiageing/Photodamage Products, 2005
    • Table 2.4 Estimated Global Sales & Forecasts of Products for Pigmentation Conditions, 2004-2012
    • Table 2.5 Pharmaceutical Products to Treat Common Dermal Pigmentation, 2005
    • Table 2.6 Estimated Global Sales & Forecasts of Antiobesity Drugs, 2004-2012
    • Table 3.1 Drugs in Development for Alopecia, 2005
    • Table 3.2 Drugs in Development for Dermal Ageing, 2005
    • Table 3.3 Drugs in Development for Pigmentation Disorders, 2005
    • Table 3.4 Drugs in Development for Gynoid Lipodystrophy (Cellulite), 2005
    • Table 3.5 Drugs in Development for Obesity, 2005
    • Table 3.6 Drugs in Development for Appetite Stimulation and Lipodystrophy, 2005
    • Table 4.1 Global Drug Market for Dermatological Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
  • List of Figures
    • Figure 1.1 Factors Involved in Normal Body Weight Regulation
    • Figure 2.1 Projected Growth Rates for Alopecia Drugs, 2005-2012
    • Figure 2.2 Estimated Global Sales of Alopecia Drugs, 2004-2012
    • Figure 2.3 Projected Growth Rates for Cutaneous Antiageing Products, 2005 & 2012
    • Figure 2.4 Estimated Global Sales of Dermal Antiageing Products, 2004-2012
    • Figure 2.5 Projected Growth Rates of Products for Pigmentation Conditions, 2005 & 2012
    • Figure 2.6 Estimated Global Sales of Products for Pigmentation Conditions, 2004-2012
    • Figure 2.7 Projected Growth Rates of Current Antiobesity Drugs, 2005-2012
    • Figure 2.8 Estimated Global Sales of Antiobesity Drugs, 2004-2012
    • Figure 2.9 Main Drivers of Growth in the Antiobesity Pharmacotherapeutic Market
    • Figure 4.1 Dermatological Therapy Area Forecasts, 2005 & 2012 (US$m)
    • Figure 4.2 Market Share of Dermatological Therapy Areas, 2005 & 2012
    • Figure 4.3 Comparative Analysis of Leading Dermatology Products, 2004-2012 (US$m)
    • Figure 4.4 Key Alopecia Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
    • Figure 4.5 Key Dermal Ageing Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
    • Figure 4.6 Key Dermal Pigmentation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
    • Figure 4.7 Key Lipodermal Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
+44 20 8816 8548

Ask a question about Global Image Dermatology Drug Market, 2005-2012, The

Enter the characters you see in the picture below
Captcha